Republican Committeeman: US-China Talks Need to Address Biomedical Practices

TO GO WITH Health-flu-China-company-Sinovac-vaccine by Francois Bougon Lab technicians work at Chinese biotech firm Sinovac in Beijing on August 24, 2009. Up-and-coming Chinese biotech firm Sinovac, already listed in the US, could get a significant boost abroad after securing government approval to produce its one-dose swine flu vaccine. China on September 3, 2009 granted approval to the country's first homegrown swine flu vaccine, which producer Sinovac says is effective after only one dose. AFP PHOTP / Peter PARKS Photo credit should read PETER PARKS/AFP via Getty Images

As the coronavirus spreads through China, and abroad, the Chinese regime’s biomedical practices are becoming a heavier focus—both abroad, and in China where CCP leader Xi Jinping recently declared that biolab safety needs to be an issue of national security.

In this episode of The China Report, we speak with Shawn Steel, California committeeman for the Republican National Committee, about why US-China relations need to go beyond trade, and begin to discuss China’s biomedical practices.